Vancouver, British Columbia--(Newsfile Corp. - October 15, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange ("CSE"). Trading is expected to commence on CSE under symbol "VIVI" at the open of markets on October 15, 2025.
Further, the board of directors (the "Board") of the Company announced today that it has received and accepted the resignation of Mr. Ran Enoch, as Director of the Company, effective as of October 10, 2025. The Board would like to thank Mr. Enoch for his service to the Company.
The Company is also pleased to announce the appointment of Julia Becker as a director of the Company effective as of October 10, 2025.
Ms. Becker is founder & President of Strike Communications Inc., a boutique firm specializing in investor relations, capital markets strategy, and corporate communications. She has 15 years of experience advising publicly listed issuers and private companies going public on overall capital markets strategy and support. This includes capital raising, investor introductions, corporate communications and investors messaging, and strategic value creation. Ms. Becker has a strong, and credible network of institutional and retail investors, analysts and investment banks across North America. Her prior roles include senior leadership positions in technology, consumer goods, gaming, healthcare and mining sectors.
For additional information on Ms. Becker's appointment and Mr. Enoch's resignation, please refer to the Company's filing statement dated October 10, 2025, available on the Company's SEDAR+ profile at www.sedarplus.ca.
About TempraMed Technologies Ltd.
TempraMed is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, space-grade thermal insulation hassle-free devices that work 24/7 for years without charging or external power. With a proven product line including VIVI Cap and VIVI Epi, and a smart technology platform on the horizon, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. With operations in North America, Europe, and Asia, TempraMed is advancing the future of medication protection and adherence.
Investors interested learning more about TempraMed are encouraged to contact the Company at:
ir@tempramed.com
www.tempramed.com
Ron Nagar
Chief Executive Officer
TempraMed Technologies Ltd.
Investor Contacts:
Julia Becker
Vice President, Capital Markets
T: +1 (604) 785-0850
E: julia@tempramed.com
The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state of the United States in which such offer, solicitation or sale would be unlawful.
Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Transaction and the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulations. These factors include, but are not limited to, those factors discussed under the heading "Risk Factors" in the Prospectus; and other risk factors as detailed from time to time. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the Transaction will be completed and that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270436
SOURCE: TempraMed
